Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication

Authors

Johannes Krisam (ORCID: https://orcid.org/0000-0003-4092-7874)
Sabine Käyser (ORCID: https://orcid.org/0000-0003-3796-8843)
Lukas Baumann (ORCID: https://orcid.org/0000-0001-7931-7470)
Carsten Müller‐Tidow (ORCID: https://orcid.org/0000-0002-7166-5232)
Lucian Le Cornet
Markus Kratzmann
Sonia Jaramillo (ORCID: https://orcid.org/0000-0002-2397-3070)
Richard F. Schlenk (ORCID: https://orcid.org/0000-0003-2215-2059)
Meinhard Kieser (ORCID: https://orcid.org/0000-0003-2402-4333)
Christoph Schliemann (ORCID: https://orcid.org/0000-0003-1755-9583)
Uwe Platzbecker (ORCID: https://orcid.org/0000-0003-1863-3239)
Martin Kaufmann (ORCID: https://orcid.org/0000-0003-0163-2205)

Institutions

Heidelberg University (DE)
University Hospital Heidelberg (DE)
Robert Bosch Hospital (DE)
University Hospital Münster (DE)
National Center for Tumor Diseases (DE)
University Hospital Leipzig (DE)

Publication Details

Journal: Haematologica
Published: 2025-11-20
DOI: https://doi.org/10.3324/haematol.2025.288362
Primary Topic: Acute Myeloid Leukemia Research
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Pfizer
AstraZeneca
Jazz Pharmaceuticals
PharmaMar
Daiichi Sankyo Europe

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication

Johannes Krisam, Sabine Käyser, Lukas Baumann, Carsten Müller‐Tidow et al.

Nov 20, 2025

Haematologica

Acute Myeloid Leukemia Research

article

Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication

Johannes Krisam, Sabine Käyser, Lukas Baumann, Carsten Müller‐Tidow, Lucian Le Cornet, Markus Kratzmann, Sonia Jaramillo, Richard F. Schlenk, Meinhard Kieser, Christoph Schliemann, Uwe Platzbecker, Martin Kaufmann

November 20, 2025article en

Abstract

No abstract available for this paper.

Haematologica

Heidelberg University (DE), University Hospital Heidelberg (DE), Robert Bosch Hospital (DE), University Hospital Münster (DE), National Center for Tumor Diseases (DE), University Hospital Leipzig (DE)

Pfizer, AstraZeneca, Jazz Pharmaceuticals, PharmaMar, Daiichi Sankyo Europe

Openalex Percentile: Top 54%

Acute Myeloid Leukemia Research

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication — Johannes Krisam, Sabine Käyser, et al. · Haematologica (2025) | TGRS Research Map | TGRS